MiNK Therapeutics, Inc.
corporate_fare Company Profile
MiNK Therapeutics, Inc. (NASDAQ:INKT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 15 items for INKT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 8/10. Across its 15 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for INKT spans 10-Q, 8-K, DEF 14A, 10-K.
Recent high-impact activity:
- MiNK 10-Q: Going-Concern Warning, $7.5M Cash, First $0.2M Product Revenue
- MiNK Matches Loss Estimates but Revenue Comes In at $200K vs $875K Expected
- MiNK's agenT-797 Selected for $87M ARPA-H Room-Temperature Cell Therapy Program
- MiNK Reports Narrower Q2 Loss and First Randomized Phase 2 Data for agenT-797
- MiNK's agenT-797 Shows Early Survival Signal in Randomized ARDS Trial
Financial Snapshot
Short Interest & Short Volume
4.29 days to coverFINRA reported short interest of 55,094 shares in INKT as of the October 30, 2026 settlement, a 15.3% increase from the prior period — about 4.3 days to cover at its recent average daily volume. On November 20, 2026, 32.3% of INKT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.